참고문헌
- Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47. https://doi.org/10.1046/j.1365-2893.1999.6120139.x
- Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S35-S46.
- Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641. https://doi.org/10.1053/j.gastro.2004.12.049
- Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-1137. https://doi.org/10.1053/jhep.2000.19347
- Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171. https://doi.org/10.1002/hep.20119
- European Association for the Study of the Liver. EASL International Consensus Conference on hepatitis C. Paris, 26-28, February 1999, Consensus Statement. J Hepatol 1999;30:956-961. https://doi.org/10.1016/S0168-8278(99)80154-8
- Tsoi KK, Ma TK, Sung JJ. Endoscopy for upper gastrointestinal bleeding: how urgent is it? Nat Rev Gastroenterol Hepatol 2009;6:463-469. https://doi.org/10.1038/nrgastro.2009.108
- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355. https://doi.org/10.7326/0003-4819-140-5-200403020-00010
- McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-593. https://doi.org/10.1056/NEJMoa0808010
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982. https://doi.org/10.1056/NEJMoa020047
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965. https://doi.org/10.1016/S0140-6736(01)06102-5
- Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652.
- Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-433. https://doi.org/10.1016/j.jhep.2005.04.009
- Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(3 Suppl 1):122S-127S. https://doi.org/10.1002/hep.510260721
- Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401. https://doi.org/10.1038/nature08309
- Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin- 28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-129. https://doi.org/10.1053/j.gastro.2010.04.013
- Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009;50:712-718. https://doi.org/10.1016/j.jhep.2008.12.017
- Hung CH, Lee CM, Lu SN. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther 2011;9:525-533. https://doi.org/10.1586/eri.11.33
- Lopez-Suarez A, Elvira-Gonzalez J, Bascunana-Quirell A, et al. Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome. Med Clin (Barc) 2006;126:321-324. https://doi.org/10.1157/13085753
- Puoti C, Bellis L, Castellacci R, Montagnese F, Bergami N, Petrone De Luca P. HCV carriers with persistently normal aminotransferase levels. Hepatology 2004;40:266-267.
- Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015;7:1617-1631. https://doi.org/10.4254/wjh.v7.i12.1617
- Pellicano R, Puglisi G, Ciancio A, et al. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection? J Med Virol 2008;80:628-631. https://doi.org/10.1002/jmv.21123
- Civantos Modino S, Guijarro de Armas MG, Monereo Mejias S, et al. Hyperuricemia and metabolic syndrome in children with overweight and obesity. Endocrinol Nutr 2012;59:533-538. https://doi.org/10.1016/j.endonu.2012.06.010
- Abreu E, Fonseca MJ, Santos AC. Association between hyperuricemia and insulin resistance. Acta Med Port 2011;24 Suppl 2:565-574.
- Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089-1097. https://doi.org/10.1038/ncb1631
- Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 2012;287:40732-40744. https://doi.org/10.1074/jbc.M112.399899
- Choi YJ, Shin HS, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest 2014;94:1114-1125. https://doi.org/10.1038/labinvest.2014.98
- Zhu Y, Hu Y, Huang T, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun 2014;447:707-714. https://doi.org/10.1016/j.bbrc.2014.04.080
- Szanto P, Grigorescu M, Dumitru I, Serban A. Steatosis in hepatitis C virus infection: response to anti-viral therapy. J Gastrointestin Liver Dis 2006;15:117-124.
피인용 문헌
- Occult hepatitis C virus infection in patients with beta‐thalassemia major: Is it a neglected and unexplained phenomenon? vol.120, pp.7, 2017, https://doi.org/10.1002/jcb.28472
- Predicting Metabolite-Disease Associations Based on Spy Strategy and ABC Algorithm vol.7, pp.None, 2020, https://doi.org/10.3389/fmolb.2020.603121